LogicBio Therapeutics, Inc.
LogicBio Therapeutics, Inc. (LOGC): 4 pipeline candidates · ~13 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
13.3 months
D/E 1.45 · 0% dilution
Lead: Phase 1/Phase 2
4 candidates
N/A
N/A
A transparent, data-derived signal for LogicBio Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$434.4M
Cash
$31.4M
Quarterly Burn
$7.2M
Runway
13.3 mo
Revenue
$2.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| lb-001 | Phase 1/Phase 2 |
| lb-301 | Preclinical |
| lb-401 | Preclinical |
| sl65-based candidates | Preclinical |
Frequently asked questions
How many drug candidates are in LogicBio Therapeutics, Inc.'s pipeline?
LogicBio Therapeutics, Inc. (LOGC) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is LogicBio Therapeutics, Inc.'s lead drug candidate?
LogicBio Therapeutics, Inc.'s most advanced tracked candidate is lb-001 (Phase 1/Phase 2) for methylmalonic acidemia.
What is LogicBio Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, LogicBio Therapeutics, Inc. has approximately 13.3 months of cash runway.
What is LogicBio Therapeutics, Inc.'s market capitalization?
LogicBio Therapeutics, Inc.'s market capitalization is approximately $434.4M.
Who is the CEO of LogicBio Therapeutics, Inc.?
Frederic Chereau is the chief executive officer of LogicBio Therapeutics, Inc. (LOGC).
Get the full picture on LogicBio Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.